U.S. Markets closed

FDA investigating two deaths of patients taking Lilly's Zyprexa

The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa.